checkAd

     169  0 Kommentare Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

    NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R. Plews, PhD will be presenting at the Los Angeles Bioscience Ecosystem Summit Twenty 24 (“LA-BEST”) conference on Thursday May 23, 2024.

    LA-BEST is the premier showcase for bioscience innovation hosted by UCLA Technology Development Group (UCLA TDG). The event is a collaboration of ~1,000 participants across the Los Angeles area to promote biotech innovation and to foster partnerships between academic institutions, the investment community, and the biopharma industry. Leading bioscience translational research programs and startups will be showcased where Southern California Institutions have significant expertise, pioneering research, and resource commitments directed toward developing innovative patient therapies.

    Details

    Dr. Plews will speak as part of the session titled “Hot Topic: Metabolism”, where invited panelists will discuss the current gaps in obesity knowledge and technology, and emerging solutions. Dr. Plews will be presenting Elevai Biosciences’ engineered probiotic approach for muscle loss prevention in combination with one or more GLP-1 receptor agonists in obesity.

    “Myostatin is being tested in combination with GLP-1 drugs as it’s demonstrated to be a clinically validated target with potential in muscle mass and strength building," said Dr. Jordan R. Plews, PhD Chief Executive Officer of Elevai. "I’m excited to share with the scientific and investment community at LA-BEST why we believe that our lead clinical candidate EL-22 offers a differentiated, oral approach as compared to other myostatin strategies being tested in obesity. Our approach induces mucosal immunity through the body’s own anti-myostatin antibodies, which could have an important role in addressing the unmet medical need of obese patients, who need to preserve muscle while losing weight.”

    Seite 1 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) - Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R. Plews, PhD will be presenting at the …